MovDisordV3, Ncbi, Merge, bibRecord, 002969

Parkinsonism in patients with a history of amphetamine exposure

Identifieur interne : 002969 ( Ncbi/Merge ); précédent : 002968; suivant : 002970

Parkinsonism in patients with a history of amphetamine exposure

Auteurs : Chadwick W. Christine [États-Unis] ; Elisabeth R. Garwood ; Lauren E. Schrock ; Daniel E. Austin ; Charles E. Mcculloch [États-Unis]

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2010.

RBID : PMC:2831101

English descriptors

KwdEn :
- Adult, Amphetamine (poisoning), Amphetamine-Related Disorders (epidemiology), Amphetamine-Related Disorders (etiology), Case-Control Studies, Dopamine Agents (poisoning), Environmental Exposure, Female, Follow-Up Studies, Humans, Male, Medical Records, Middle Aged, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (epidemiology), Parkinsonian Disorders (physiopathology), Questionnaires, Retrospective Studies, Risk Factors, Time Factors.
MESH :
- chemical , poisoning : Amphetamine, Dopamine Agents.
- chemically induced : Parkinsonian Disorders.
- epidemiology : Amphetamine-Related Disorders, Parkinsonian Disorders.
- etiology : Amphetamine-Related Disorders.
- physiopathology : Parkinsonian Disorders.
- Adult, Case-Control Studies, Environmental Exposure, Female, Follow-Up Studies, Humans, Male, Medical Records, Middle Aged, Questionnaires, Retrospective Studies, Risk Factors, Time Factors.

Abstract

We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g. manganese), we sought to compare the clinical features of PD patients with prolonged amphetamine exposure with unexposed PD patients. Prolonged exposure was defined as a minimum of twice a week for ≥ 3 months, or weekly use ≥ 1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ±7.4 years; p < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831101

DOI: 10.1002/mds.22915
PubMed: 20063432
PubMed Central: 2831101

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: 000076
to stream Pmc, to step Curation: 000076
to stream Pmc, to step Checkpoint: 000319
to stream PubMed, to step Corpus: 001A33
to stream PubMed, to step Curation: 001A33
to stream PubMed, to step Checkpoint: 001710

Links to Exploration step

PMC:2831101

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Neurology, University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Neurology, University of California</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation><nlm:aff id="A2">Pennsylvania State University College of Medicine</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation><nlm:aff id="A3">Department of Neurology, University of Utah</nlm:aff>
<wicri:noCountry code="subfield">University of Utah</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation><nlm:aff id="A4">Colby College</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="3"><nlm:aff id="A5">Department of Epidemiology and Biostatistics University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Epidemiology and Biostatistics University of California</wicri:orgArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">20063432</idno>
<idno type="pmc">2831101</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831101</idno>
<idno type="RBID">PMC:2831101</idno>
<idno type="doi">10.1002/mds.22915</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">000076</idno>
<idno type="wicri:Area/Pmc/Curation">000076</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000319</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001A33</idno>
<idno type="wicri:Area/PubMed/Curation">001A33</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001710</idno>
<idno type="wicri:Area/Ncbi/Merge">002969</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Neurology, University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Neurology, University of California</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation><nlm:aff id="A2">Pennsylvania State University College of Medicine</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation><nlm:aff id="A3">Department of Neurology, University of Utah</nlm:aff>
<wicri:noCountry code="subfield">University of Utah</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation><nlm:aff id="A4">Colby College</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="3"><nlm:aff id="A5">Department of Epidemiology and Biostatistics University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Epidemiology and Biostatistics University of California</wicri:orgArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Amphetamine (poisoning)</term>
<term>Amphetamine-Related Disorders (epidemiology)</term>
<term>Amphetamine-Related Disorders (etiology)</term>
<term>Case-Control Studies</term>
<term>Dopamine Agents (poisoning)</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Parkinsonian Disorders (chemically induced)</term>
<term>Parkinsonian Disorders (epidemiology)</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="poisoning" xml:lang="en"><term>Amphetamine</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Case-Control Studies</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P6">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g. manganese), we sought to compare the clinical features of PD patients with <italic>prolonged</italic>
 amphetamine exposure with unexposed PD patients. <underline>Prolonged exposure</underline>
 was defined as a minimum of twice a week for ≥ 3 months, or weekly use ≥ 1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ±7.4 years; p < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.</p>
</div>
</front>
</TEI>
<double pmid="20063432"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Neurology, University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Neurology, University of California</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation><nlm:aff id="A2">Pennsylvania State University College of Medicine</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation><nlm:aff id="A3">Department of Neurology, University of Utah</nlm:aff>
<wicri:noCountry code="subfield">University of Utah</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation><nlm:aff id="A4">Colby College</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="3"><nlm:aff id="A5">Department of Epidemiology and Biostatistics University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Epidemiology and Biostatistics University of California</wicri:orgArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">20063432</idno>
<idno type="pmc">2831101</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831101</idno>
<idno type="RBID">PMC:2831101</idno>
<idno type="doi">10.1002/mds.22915</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">000076</idno>
<idno type="wicri:Area/Pmc/Curation">000076</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000319</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Neurology, University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Neurology, University of California</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation><nlm:aff id="A2">Pennsylvania State University College of Medicine</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation><nlm:aff id="A3">Department of Neurology, University of Utah</nlm:aff>
<wicri:noCountry code="subfield">University of Utah</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation><nlm:aff id="A4">Colby College</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="3"><nlm:aff id="A5">Department of Epidemiology and Biostatistics University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Epidemiology and Biostatistics University of California</wicri:orgArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P6">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g. manganese), we sought to compare the clinical features of PD patients with <italic>prolonged</italic>
 amphetamine exposure with unexposed PD patients. <underline>Prolonged exposure</underline>
 was defined as a minimum of twice a week for ≥ 3 months, or weekly use ≥ 1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ±7.4 years; p < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.</p>
</div>
</front>
</TEI>
</pmc>
<pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure.</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W" last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of California, San Francisco, CA 94143, USA. chad.christine@ucsf.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of California, San Francisco, CA 94143</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R" last="Garwood">Elisabeth R. Garwood</name>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E" last="Schrock">Lauren E. Schrock</name>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E" last="Austin">Daniel E. Austin</name>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E" last="Mcculloch">Charles E. Mcculloch</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="doi">10.1002/mds.22915</idno>
<idno type="RBID">pubmed:20063432</idno>
<idno type="pmid">20063432</idno>
<idno type="wicri:Area/PubMed/Corpus">001A33</idno>
<idno type="wicri:Area/PubMed/Curation">001A33</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001710</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure.</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W" last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of California, San Francisco, CA 94143, USA. chad.christine@ucsf.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of California, San Francisco, CA 94143</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R" last="Garwood">Elisabeth R. Garwood</name>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E" last="Schrock">Lauren E. Schrock</name>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E" last="Austin">Daniel E. Austin</name>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E" last="Mcculloch">Charles E. Mcculloch</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Amphetamine (poisoning)</term>
<term>Amphetamine-Related Disorders (epidemiology)</term>
<term>Amphetamine-Related Disorders (etiology)</term>
<term>Case-Control Studies</term>
<term>Dopamine Agents (poisoning)</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Parkinsonian Disorders (chemically induced)</term>
<term>Parkinsonian Disorders (epidemiology)</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="poisoning" xml:lang="en"><term>Amphetamine</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Case-Control Studies</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for >or=3 months, or weekly use >or=1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 +/- 8.2 years vs. 53.1 +/- 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.</div>
</front>
</TEI>
</pubmed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002969 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002969 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     PMC:2831101
   |texte=   Parkinsonism in patients with a history of amphetamine exposure
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:20063432" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Parkinsonism in patients with a history of amphetamine exposure

Parkinsonism in patients with a history of amphetamine exposure

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki